Accrual in this trial was suspended in March 2025 as a result of findings from the Checkmate 8HW trial, which showed that the ...

In this analysis, researchers aimed to evaluate the clinicopathologic characteristics, metastatic patterns, and survival outcomes in patients with metastatic prostate cancer and low-volume primary ...

HUTCHMED has commenced the Phase III stage of its ongoing Phase II/III clinical trial assessing the combination of ...

Furthermore, a near-doubling of 12-month survival was also achieved with the elraglusib regimen vs GnP alone (44.4% vs 22.3%) ...

New research presented at ASCO GI positions both agents as potent therapeutic options, with potential to redefine standard ...

A new study published in Nature Communications provides a framework for researching whether earlier, model-guided treatment ...

The Hepzato Kit is the first FDA-approved liver-directed therapy for unresectable metastatic uveal melanoma, showing ...

Zoledronic acid reduced fracture risk by 27% in men with metastatic prostate cancer receiving ADT in the STAMPEDE trial. Patients with non-metastatic disease showed no significant fracture benefit ...

Berger for the latest episode of the “Cancer Horizons” podcast to discuss frontline treatment options for patients with metastatic triple-negative breast cancer. Berger, who recently spoke at CURE’s ...

At the San Antonio Breast Cancer Symposium (SABCS), investigators outlined the rationale and design of the ERADICATE, a first ...